SCHEMBL23214655

SCHEMBL23214655

CC(C)CC(Br)c1cc(Cl)c(Cl)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
HPGD P15428 2/20 0.37
TSHR P16473 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRB1 P18505 1/20 0.31
HSP90AA1 P07900 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPK1 P28482 2/20 0.30
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
PTGES O14684 1/20 0.30
ALOX5 P09917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214636 0.81 LMNA (0.41) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL23214743 0.79 LMNA (0.48) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL10702604 0.73 LMNA (0.72) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL21302114 0.70 LMNA (0.50) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL26771218 0.68 LMNA (0.44) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL23214644 0.67 LMNA (0.47) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL21686455 0.63 LMNA (0.69) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL4055501 0.63 LMNA (0.52) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL5386493 0.63 LMNA (0.57) LMNAALOX15ALOX12HPGDTSHR
SCHEMBL16736820 0.63 LMNA (0.69) LMNAALOX15ALOX12HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411367-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2022-12-29 US disclosed
EP-4041228-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114727993-A Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-08 CN disclosed
WO-2021071812-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071812-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411367-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 LMNA 1864/4885ALOX15 4559/4885ALOX12 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.